ANNOUNCEMENTS

Appointment of Mr. Amey Joshi as Vice President – Human Resources

News Paper Publication

Completion Of Business Transfer Agreement With Vimta Labs Limited

Closure of Trading Window

Cessation of Independent Director

Press Release “Thyrocare Technologies Limited enters into a Business Transfer Agreement to acquire diagnostic and pathological services business of Vimta Labs Limited”.

Execution Of Business Transfer Agreement With Vimta Labs Limited.

Cessation of Independent Director

Completion of Business Transfer Agreement with Polo Labs Private Limited.

Execution of Business Transfer Agreement with Polo Labs Private Limited

Rectification Order Passed By The Income Tax Department, Mumbai For The Financial Year 2016-17

Completion of acquisition of Think Health Diagnostic Private Limited

Rectification of assessment order passed by the Navi Mumbai Municipal Corporation, Cess Department

Appointment Of Mr. Nitin Chugh As Chief Commercial Officer Of The Company W.E.F. February 22, 2024

Announcement under Regulation 30 (LODR)-Acquisition

Appointment of Mr. Rahul Guha, Managing Director and Chief Executive Officer of the Company as President – Operations and designated as Key Managerial Personnel of API Holdings Limited, Ultimate Holding Company

Closure of Trading window 

Meeting with Investors/Analysts

Intimation under Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021

Meeting with Investors/Analysts

Reg30 Disc of Assesssment Order Navi Mumbai Muncipal Corporation

Closure of Trading window 

Entered into a Subscription Agreement at Tanzania

Meeting with Investors/Analysts

Proceedings of Annual General Meeting

Advertisement Notice for Thyrocare’s Annual General Meeting

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Intimation under Regulation 30 and Regulation 30A in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“Listing Regulations”)

Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Investor call intimation

Meeting with Investors/Analysts

Newspaper Publication

Closure of Trading Window

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Announcement under Regulation 30 (LODR)-Resignation of Director

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Closure of Trading window 

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Closure of Trading window 

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Meeting with Investors/Analysts

Corporate presentation for roadshow

Investment in LLP

Meeting with Investors/Analysts

Schedule Of Analysts/Institutional Investor Meet/Con. Call

Intimation of Board Meeting to be held on Friday 11, November , 2022 inter alia, to consider and approve the unaudited Financial results (both Stand-alone  and Consolidated) for the quarter / half year ended September 30, 2022.

Intimation that Trading Window shall remain closed for Directors / Designated Employees / Connected Persons with effect from 01 October 2022, and would be re-opened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the Quarter  / Half Year ended September 30, 2022.

Schedule Of Analysts/Institutional Investor Meet/Con. Call

Intimation of allotment of 26,711 Equity Shares pursuant to exercise of ESOPs under ESOP Scheme 2019 

Schedule Of Analysts/Institutional Investor Meet/Con. Call      

Transcript of Earnings Call held on 02-08-2022

22nd Annual General Meeting – Proceedings.

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing copies of newspaper advertisement of unaudited financial results for the Quarter ended 30th June 2022, published in Free Press Journal (English) and Pudhari (Marathi) in the prescribed format.  

  https://investor.thyrocare.com/wp-content/uploads/2022/08/THY0220220802142236-3.mp3

Presentation on Audited Financial Results for the quarter ended June 30, 2022.

Intimation of decision taken at the Board Meeting held on August 01, 2022- (i) approval of the Unaudited Financial Results (both Stand-alone and Consolidated) for the quarter ended June 30, 2022

Intimation about conference call for Indian and Overseas Investors to be held on Tuesday, August 02, 2022  to discuss about Unaudited financial results (Stand-alone and Consolidated) for the quarter ended June 30, 2022. Click here to see the invite

Intimation of Board Meeting to be held on Monday 01, August, 2022 inter alia, to consider and approve the unaudited Financial results (both Stand-alone  and Consolidated) for the quarter ended June 30, 2022.

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the copy of the newspaper advertisement published in Free Press Journal (English) and Pudari (Marathi)

Pursuant to the provisions of Section 91 of the Act, the Register of Members and Share Transfer Books of the Company will remain closed from Wednesday, July 27, 2022 to, August 03, 2022 (both days inclusive) in connection with the AGM

Intimation about 22nd   Annual General Meeting will be on Wednesday, August 03, 2022 at 4.00 P.M. at the Corporate office of the Company situated at D-37/3, TTC, Industrial Area, MIDC, Turbhe, Navi Mumbai-400073.

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from July 01, 2022, and would be re-opened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the quarter ended June 30, 2022

Transcript of Earnings Call held on 06-05-2022

https://investor.thyrocare.com/wp-content/uploads/2022/05/TR916020220506140972.mp3          

Mr. Rahul Guha has taken charge as the Managing Director & Chief Executive Officer with effect from Wednesday, May 04, 2022. Mr. Rahul Guha will also function as the Managing Director & CEO of Nueclear Healthcare Limited, our wholly owned subsidiary. Mr. Dharmil Sheth, who was appointed as the Managing Director for the interim period to comply with the provisions of Sec. 203 (4) of the Companies Act, 2013, has demitted office effective from Wednesday, May 04, 2022 and will continue to be a Non-Executive, Non-Independent Director of the Company.Intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that a conference call for the Indian and overseas analysts is arranged by our management to discuss the Company’s financial results for Quarter / Whole year ended March 31, 2022, on Friday, May 06, 2022 at 04.00 p.m. local time.Investorscallrevised

We wish to intimate that a conference call for the Indian and overseas analysts is arranged by our management to discuss the Company’s financial results for Quarter / Whole year ended March 31, 2022, on Friday, May 06, 2022 at 04.00 p.m. local time. Mr. Rahul Guha, MD & CEO Designate, who will take charge tomorrow, the 4th May 2022, and Mr. Sachin Salvi, Chief Financial Officer, will represent the Company .Investorscall

Presentation on Audited Financial Results for the quarter / whole year ended 31-03-2022InvestorsPresentation31032022

Intimation of decisions taken at the Board Meeting held on April 29, 2022, about approved the Audited Financial Results (Stand-alone and Consolidated) for the Financial Year ended March 31, 2022 and have also decided to declare an interim dividend at the rate of Rs. 15.00 (Rupees Fifteen only) per share (150% of the face value of Rs. 10/- each) for the financial year 2021-22. The Board has fixed, Thursday 12th May 2022 as the record date for the purpose of determining the entitlement of shareholders for the interim dividend.

Intimation about Board Meeting scheduled to be held on Friday, April 29 ,2022 inter alia, to consider and approve the audited financial results (both Stand-alone and Consolidated) for the quarter / Financial year ended 31st March 2022.

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from April 01, 2022, and would be re-opened after 48 hours of date of announcement / declaration of Audited Financial Results for the Financial Year ended March 31, 2022

Pursuant to Regulation 30 and Regulation 31(8)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company has received approval from the National Stock Exchange of India and BSE Ltd. for reclassification of the outgoing Promoters and Promoter Group shareholders from Promoter category to to public category in accordance with the Regulation 31A (10) of SEBI (Listing and Disclosure requirements), Regulation 2015. https://investor.thyrocare.com/wp-content/uploads/2022/03/IntimationtoNSEandBSEforapprovalofreclassficationofshares.pdf

Presentation – Unaudited financial results for the quarter/nine months period ended 31-12-2021.https://investor.thyrocare.com/wp-content/uploads/2022/03/Presentationupdate.pdf

Intimation of decision taken at the Board Meeting held on February 12, 2022 to approved the unaudited Financial Results (Stand-alone and Consolidated) for the Quarter / Nine months ended December 31, 2021, and appointed Mr. Dharmil Sheth as Managing Director with effect from 12-02-2022 till the time Mr. Rahul Guha takes charge as MD and CEO.

The Board of Directors have, in order to comply with the provisions of Sub-Section 4 of Section 203 of the Companies Act, 2013, appointed Mr. Dharmil Sheth, presently a non-independent, non-executive director, to hold the position of Managing Director with effect from 12-02-2022 till the time Mr. Rahul Guha takes charge as MD and CEO.

Intimation about Board Meeting scheduled to be held on Saturday, February 12,2022 inter alia, to consider and approve the unaudited financial results (both Stand-alone and Consolidated) for the quarter / nine months ended 31st December 2021.

Press Release being issued by the Company for the appointment of Mr. Rahul Guha as the Managing Director & Chief Executive Officer of the Company. Enclosed press release:https://investor.thyrocare.com/wp-content/uploads/2022/02/Epic-Press-Release.docx-3.pdf

The Board of Directors of the Company, at their meeting held on Saturday, 05th February, 2022, have approved appointment of  Mr. Rahul Guha as the Managing Director & Chief Executive Officer of the Company. He will be joining by May 2022.

The Board of Directors of the Company, at their meeting held on January 28, 2022, based on the recommendations of the Nomination & Remuneration Committee and Audit Committee, have appointed Mr. Sachin Salvi, presently working as Senior Vice President – Finance as the Chief Financial Officer of the Company with effect from January 28, 2022.

Intimation of decision taken at the Board Meeting held on January 28, 2022 to approve the following Special Purpose Interim Consolidated financial statements – For the period 1st April to 30th November 2021 and for the stub period 2nd September to 30th November 2021. Approved the Restated financial statements for the stub period 2nd September to 30th November 2021.The Board has appointed Mr. Sachin Salvi, presently working as Senior Vice-President-Finance, as Chief Financial Officer of the Company effective from today, 28th January 2022

Intimation of decision taken at the Board Meeting held on January 10, 2022 for approval for sharing financials statements for the period 1st April to 30th September 2021, For the period 1st April to 1st September 2021, For the period 2nd September to 30th September 2021 with API Holdings Limited.

Intimation of decision taken at the Board Meeting held on December 16, 2021 for approval for sharing certain financial information (Stand-alone and Consolidated) of the Company with API Holdings Limited .

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from 1st January, 2022 and will be reopened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the Quarter/Nine Months ended December 31, 2021.

Intimation of decision taken at the Board Meeting held on November 13, 2021- (i) approval of the Unaudited Financial Results (both Stand-alone and Consolidated) for the quarter /half year ended on 30-09-2021.

Intimation about Board Meeting scheduled to be held on Saturday, November 13, 2021, inter alia, to consider and approve the unaudited financial results (both Stand-alone and Consolidated) for the quarter / half year ended 30th September 2021

Intimation regarding allotment of 28913 Equity Shares to 158 eligible employees after obtaining required approvals from Stock Exchanges.

The Board of Directors of the Company, at their meeting held on 27th October 2021 has- 1)  Approved the Audited Special Purpose Consolidated financial statements of the Company as on 30th June 2021, to be included in the DRHP of API Holdings Ltd., who are holding company of Docon Technologies Limited, who are our holding company. 2) Noted the Management Accounts of the Company (unaudited, not reviewed) as on 30th September 2021 which would be shared with API Holdings Limited and their merchant bankers to give them comfort with respect to their DRHP. This will not be published or shared with any other individual/entity as it might be considered as unpublished price sensitive information. 3)  Approved the proposal, based on the recommendation of the Audit Committee, to enter into an agreement for outsourcing the processing of samples and generating report, with API Holdings Ltd., who are a Related Party under statutory provisions.

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from 1st October, 2021 and will be reopened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the quarter and half year ended September 30, 2021.

Intimation of decision taken at the Board Meeting held on August 12, 2021- (i) approval of the Unaudited Financial Results (both Stand-alone and Consolidated) for the quarter ended on 30-06-2021.

Intimation about Board Meeting scheduled to be held on Thursday, August 12, 2021, inter alia, to consider and approve the unaudited financial results (both Stand-alone and Consolidated) for the quarter ended 30th June 2021.

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from 1st July, 2021 and will be reopened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the Quarter ended June 30, 2021.

Intimation about execution of a share purchase agreement dated 25 June 2021 between members of the promoter and promoter group of Thyrocare Technologies Limited (“Company”) (i.e., Dr. A. Velumani, A. Sundararaju HUF, A. Velumani HUF, Amruta Velumani, Anand Velumani, A. Sundararaju, Thyrocare Properties and Infrastructure Private Limited, Pavilion Commercial Private Limited, Thyrocare Publications LLP, Sumathi Infra Project LLP and Mahima Advertising LLP) (“Sellers”) and  Docon Technologies Private Limited (“Acquirer”), the Sellers have agreed to sell to the Acquirer their entire shareholding in the Company, being equivalent to approximately 66.14% of the equity share capital of the Company (on a fully diluted basis) and being equivalent to 3,49,72,999 equity shares of the Company (collectively, the “Sale Shares”), and the Acquirer has agreed to purchase the Sale Shares from the Sellers in accordance with the share purchase agreement, completion of which is subject to certain conditions precedent  (“Share Purchase Agreement”).View Here

Intimation about (i) 21st  Annual General Meeting convened to be held on Saturday, June 26, 2021 at 3.00 P.M. through Video Conferencing (VC) / Other Audio Visual Means (OAVM) & (ii) E-voting facility available to the Shareholders prior to the AGM and during the AGM.

Intimation of decisions taken at the Board Meeting held on May 8, 2021, about approval of the Audited Financial Statements (both Stand-alone and Consolidated) for the quarter and the whole year ended 31-03-2021, Recommendation of a Dividend of Rs.15/- per share for 2020-21 and granting of Stock Options to the eligible employees of the Company for the year 2020-21.

Intimation about Board Meeting scheduled to be held on Saturday, May 8, 2021, inter alia, to consider and approve the audited financial results (both Stand-alone and Consolidated) for the year ended 31st March 2021, to consider recommending final dividend, if any, for the financial year 2020-21, and to consider granting of stock options to employees for 2020-21.

Intimation of business update about increased turnover in Q4, enhancement on the RT-PCR testing capacity of laboratories at Navi Mumbai & Gurgaon, approval of the Covid testing facility in Bangalore by NABL, completion of more than one million Covid tests as on 31-03-2021, etc. View Here

Intimation that Trading Window shall remain closed for Directors / Designated Employees / Connected Persons with effect from 1st April, 2021, and would be re-opened after 48 hours of date of announcement / declaration of Audited Financial Results for the Year ended March 31, 2021.

Intimation about the Con-call with the representative(s) of First State Sentier, at 09.00 A.M. on Monday, March 08, 2021.

Intimation about Transcript of the Earnings Call held on Thursday, February 04, 2021 at 05.00 P.M. local time of Indian and Overseas Investors, post declaration of the Company’s Unaudited Financial Results (stand-alone & consolidated) for the Quarter / Nine Months ended 31-12-2020. Click here

Intimation about the con-calls with the representatives of the following organizations: (i) Mirabilis Investment Trust, at 05.00 P.M. on Monday, February 15, 2021. (ii) Arisaig Partners, at 03.00 P.M. on Friday, February 19, 2021.

Intimation about conference call for Indian and Overseas Investors to be held on Thursday, February 04, 2021 to discuss about Unaudited financial results (Stand-alone and Consolidated) for the quarter / nine months ended 31-12-2020. Click here to see the invite

Intimation of outcome of the Board Meeting held on January 30, 2021, as follows: 1) The Board approved Unaudited Financial Results (both Stand-alone and Consolidated) for the quarter / Nine Months ended 31-12-2020. 2) The Board decided to defer the question of further dividend to the next meeting. 3) With regard to appointment of new Auditors, the Board authorized Dr. A. Velumani, Chairman & Managing Director, Mr. A. Sundararaju, Executive Director & CFO and Mr. G.S. Hegde, Independent Director, to take a decision and report to the Committee / Board at the earliest.

Intimation about Board Meeting scheduled to be held on Saturday, January 30, 2021, inter alia, to consider and approve the unaudited financial results (both Stand-alone and Consolidated) for the quarter / nine months ended 31st December, 2020, to consider and decide on payment of further interim dividend, if any, for the financial year 2020-21, and to consider appointment of new auditors in the place of current auditors whose term would expire shortly.

Intimation about (1) significant business revival in Q3 of the current financial year, after business activities resumed across all states, and the growth in the non-covid business and (2) increase in volume of RT-PCR tests making us most cost effective service provider to the patients. View Here

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from 1st January, 2021 and will be reopened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the quarter / nine months ended December 31, 2020.

Intimation regarding allotment of 38054 Equity Shares to 135 eligible employees after obtaining required approvals from Stock Exchanges.

Intimation about the Con-call with the representative(s) of Grandeur Peak Global Advisors, at 10.00 A.M. on Tuesday, December 08, 2020.

Intimation about the Con-call with the representative(s) of Wellington Management Hong Kong Ltd., at 11.30 A.M. on Tuesday, November 24, 2020.

Intimation about the Con-call (Zoom Meeting) with the representative(s) of Arisaig Partners, at 05.00 P.M. today, i.e. on Tuesday, November 10, 2020.

Intimation about Transcript of the Earnings Call held on Tuesday, November 03, 2020 at 12.00 Noon local time of Indian and Overseas Investors, post declaration of the Company’s Unaudited Financial Results (stand-alone & consolidated) for the Quarter / Half Year ended 30-09-2020. Click here

Intimation about conference call for Indian and Overseas Investors to be held on Tuesday, November 03, 2020 to discuss about Unaudited financial results (Stand-alone and Consolidated) for the quarter / half year ended 30-09-2020. Click here to see the invite

Intimation of outcome of the Board Meeting held on October 28, 2020, as follows: 1) The Board approved Unaudited Financial Results (both Stand-alone and Consolidated) for the quarter / half year ended on 30-09-2020. 2) The Board declared an interim dividend of Rs.10/- per share for FY 2020-21. 3) The Board took on record the following changes of the Key Managerial Personnel: i. Dr. A. Velumani, Chairman, has been reappointed as Managing Director ii. Mr. A. Sundararaju, has been reappointed as Executive Director & Chief Financial Officer iii. Mr. Arindam Haldar has been appointed as Chief Executive Officer.

Intimation about Board Meeting scheduled to be held on Wednesday, October 28, 2020, inter alia, to consider and approve the unaudited financial results (both Stand-alone and Consolidated) for the quarter / half year ended 30th September 2020, and to consider and decide on payment of interim dividend, if any, for the financial year 2020-21.

Intimation regarding business update on COVID-19 RT-PCR tests and COVID Antibody tests as on September 30, 2020.  The Company has also started RT-PCR tests from  its Laboratory situated at Gurgaon, Delhi and will create the same kind of facilities at Banglore and Kolkata. View Here

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from 1st October, 2020 and will be reopened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the quarter and half year ended September 30, 2020.

Intimation about the con-calls with the representatives of the following organizations: (i) Nomura Asset Management Singapore Ltd., at 11.00 A.M. on Wednesday, September 23, 2020. (ii) Acacia Partners, at 03.30 P.M. on Wednesday, September 23, 2020. (iii) Earnest Innovation Partners Pvt. Ltd., at 11.00 A.M. on Thursday, September 24, 2020. (iv) Abakkus Asset Manager LLP, at 03.30 P.M. on Thursday, September 24, 2020.

Intimation regarding appointment of Mr. Arindam Haldar as Chief Executive Officer (CEO) of the Company w.e.f. September 14, 2020. View Here

Intimation of decisions taken at the Board Meeting held on September 10, 2020, authorizing Dr. A. Velumani, Chairman & Managing Director, to identify and appoint a suitable candidate as a professional Chief Executive Officer for the Company. The Board also authorized Dr. A. Velumani, Chairman, to identify competent candidates for the positions of Managing Director, Executive Director, and other senior positions at his discretion.

Intimation about the Con-call (Zoom Meeting) with the representative(s) of Arisaig Partners, at 05.30 P.M. on Thursday, September 10, 2020.

Intimation about (i) 20th Annual General Meeting convened to be held on Tuesday, September 29, 2020 at 3.00 P.M. through Video Conferencing (VC) / Other Audio Visual Means (OAVM) & (ii) E-voting facility available to the Shareholders prior to the AGM and during the AGM.

Intimation about the Con-call with the representative(s) of Sylebra Capital Limited, at 11.30 A.M. on Monday, September 07, 2020.

Intimation about Board Meeting scheduled to be held on Thursday, September 10, 2020, inter alia, to discuss and decide about appointing a professional Chief Executive Officer of the Company who will function under the superintendence of the Board of Directors of the Company, headed by Dr. A. Velumani, PhD, Chairman & Managing Director.

Intimation of decisions taken at the Board Meeting held on July 31, 2020, about (i) approval of the Unaudited Financial Results (both Stand-alone and Consolidated) for the quarter ended on 30-06-2020, and (ii) decision not to declare any Interim Dividend considering the prevailing uncertain economic scenario.

Intimation about Board Meeting scheduled to be held on Friday, July 31, 2020, inter alia, to consider and approve the unaudited financial results (both Stand-alone and Consolidated) for the quarter ended 30th June 2020, and to consider and decide on payment of interim dividend, if any, for the financial year 2020-21.

Intimation about completion of 1,00,000 COVID-19 RT PCR tests in 108 days by Thyrocare at affordable cost and at minimum possible time in accordance with the relevant regulations, guidelines and instructions issued by ICMR from time to time. Also to note that the Company has started testing for COVID Antibodies from 28.06.2020 and have done more than 25,000 tests within a short span of 10 days.View Here

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from 1st July, 2020 and will be reopened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the Quarter ended June 30, 2020.

Intimation of decisions taken at the Board Meeting held on May 23, 2020, about i) approval of the Audited Financial Statements (both Stand-alone and Consolidated) for the quarter and the whole year ended 31-03-2020, ii) deferring recommendation of final dividend for the FY 2019-20, and iii) granting of Stock Options to the eligible employees for FY 2019-20.

Intimation about Board Meeting scheduled to be held on Saturday, May 23, 2020, inter alia, to consider and approve the audited financial results (both Stand-alone and Consolidated) for the year ended 31st March 2020, to consider recommending final dividend, if any, for the financial year 2019-20, and to consider granting of stock options to employees for 2019-20. Intimation about closure of Trading Window for Directors, Employees and Connected Persons from April 01, 2020 (as already announced) up to end of the day on May 26, 2020.  

Intimation about temporary suspension of PET-CT Scanning Operations at selective Centres managed/operated by our wholly-owned subsidiary, Nueclear Healthcare Limited, as a precautionary measure to ensure safety of our patients and staffs, following the decision of Government of India, to invoke the provisions of the National Disaster Management Act, 2005, to combat the spread of COVID-19.

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from 1st April, 2020 and will be reopened after 48 hours of date of announcement / declaration of Audited Financial Results for the Quarter and Year ended March 31, 2020.

Intimation about the con-calls with the representatives of the following organisations to discuss the impact of COVID-19: (i) ICICI Prudential AMC, at 02.30 P.M. on Tuesday, March 31, 2020. (ii) Premji Invest, at 03.30 P.M. on Tuesday, March 31, 2020. (iii) Nippon India Mutual Fund, at 04.00 P.M. on Wednesday, April 01, 2020.

Intimation about Con-call arranged by PhillipCapital (India) Pvt. Ltd. with Dr. A. Velumani, Chairman, Managing Director and CEO of our company, to discuss on ‘Covid-19 and its impact on Indian Healthcare’, at 02.30 P.M. today, i.e. Wednesday, March 18, 2020, and deferring of Con-call arranged through Prabhudas Lilladher Pvt. Ltd. on the same topic.

Intimation about Con-call through Prabhudas Lilladher (P) Limited, on ‘Covid-19 and Diagnostics’, at 04.00 P.M., today i.e. Wednesday, March 18, 2020.

Intimation about meeting of representative(s) of Crescita Investment Management Pvt. Ltd. with us at 04.00 P.M. on Wednesday, March 11, 2020 at the Corporate Office of the Company.

Intimation about the following forthcoming Analyst meetings: (i) Meeting with the representative(s) of J. P. Morgan India Private Limited, at 11.30 A.M. on Wednesday, March 11, 2020. (ii) Meeting with the representative(s) of Aditya Birla Capital, at 11.00 A.M. on Thursday, March 12, 2020. (iii) Meeting with the representative(s) of Hill Fort Capital Partners Limited, at 11.30 A.M. on Wednesday, March 18, 2020.

Intimation about the following forthcoming Analyst meetings: (i) Meeting with the representative(s) of QRC Investment Advisors LLP, at 11.30 A.M. on Monday, February 24, 2020. (ii) Meeting with the representative(s) of SBI Mutual Fund, at 3.00 P.M. on Monday, February 24, 2020. (iii) Meeting with the representative(s) of Ampersand Capital Partners, at 11.30 A.M. on Tuesday, February 25, 2020. (iv) Meeting with the representative(s) of Wallfort Financial Services Limited, at 4.00 P.M. on Tuesday, February 25, 2020.

Press Release – Launching of marketing Joint Venture by Thyrocare for Datar Cancer Genetics, for early detection of 16 types of cancer.View Here

Intimation about the following forthcoming Con-call: (i) Con-call with the representative(s) of Eternity Capital Management Limited, at 11.00 A.M. on Monday, February 17, 2020. (ii) Con-call with the representative(s) of Mirabilis Investment Trust, at 04.00 P.M. on Monday, February 17, 2020.

Update about closure of two centres (Surat and Baroda) of Nueclear Healthcare Limited, wholly owned subsidiary of the Company.

Intimation of decisions taken at the Board Meeting held on February 01, 2020, about (i) approval of the Unaudited Financial Results (both Stand-alone and Consolidated) for the quarter / nine months ended on 31-12-2019, (ii) deferring of further dividend to the next Meeting, (iii) reappointment of Dr. A. Velumani as Managing Director & Chief Executive Officer for a further period of five years, and (iv) reappointment of Mr. A. Sundararaju as Executive Director & Chief Financial Officer for a further period of five years.

Intimation about Board Meeting scheduled to be held on Saturday, February 01, 2020 to inter alia, consider and approve the Unaudited financial results (both Stand-alone and Consolidated) for the quarter / nine months ended December 31, 2019, payment of further interim dividend, if any, and reappointment of Dr. A. Velumani as Managing Director & CEO and Mr. A. Sundararaju as Executive Director & CFO.

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from 1st January 2020 and will be reopened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the Quarter /Nine months ended December 31, 2019.

Intimation that the Company has allotted 37,759 numbers of equity shares to 103 eligible employees of the Company, who have exercised the Options granted to them under ESOP Scheme 2016.

Intimation about meeting of representative(s) of Sundaram Asset Management Company Limited, with us at 10.30 A.M. on Saturday, December 14, 2019 at the Corporate Office of the Company.

Intimation about the following forthcoming Analyst meetings: (i) Meeting with the representative(s) of Banyan Capital Advisors LLP, at 11.30 A.M. on Monday, December 09, 2019. (ii) Meeting with the representative(s) of PhillipCapital (India) Pvt. Ltd., at 03.30 P.M. on Wednesday, December 11, 2019. (iii) Meeting with the representative(s) of Arisaig Partners, at 11.00 A.M. on Monday, December 16, 2019. (iv) Meeting with the representative(s) of Spark Capital Advisors (I) Pvt. Ltd., at 11.00 A.M. on Tuesday, December 17, 2019, to be followed by a visit by them to our lab.

Intimation about the following forthcoming Con-call / Analyst meeting: (i) Con-call with the representative(s) of Nippon India Mutual Fund, at 04.00 P.M. on Tuesday, December 03, 2019. (ii) Meeting with the representative(s) of ADD Capital, at 03.30 P.M. on Wednesday, December 04, 2019, at the Corporate Office of the Company.

Intimation about meeting of representative(s) of InvesQ Investment Advisors, with us at 11.00 A.M. on Friday, November 29, 2019 at the Corporate Office of the Company.

Intimation about the following forthcoming Con-call / Analyst meeting: (i) Con-call with the representative(s) of Eternity Capital Management Limited, at 11.30 A.M. on Monday, November 25, 2019. (ii) Meeting with the representative(s) of Capital Investment Research Services Private Limited (Capital Group), at 10.30 A.M. on Monday, December 02, 2019, at the Corporate Office of the Company.

Intimation about the following forthcoming Con-call / Analyst meeting: (i) Con-call with the representative(s) of Bajaj Allianz, Pune, at 04.00 P.M. on Thursday, November 21, 2019. (ii) Meeting with the representative(s) of Vishuddha Capital Management, at 03.00 P.M. on Friday, November 22, 2019, at the Corporate Office of the Company.

Intimation of decisions taken at the Board Meeting held on November 07, 2019, about approval of the Unaudited Financial Results (both Stand-alone and Consolidated) for the quarter / half year ended on 30-09-2019 and declaration of interim dividend of Rs.5/- per share for FY 2019-20, and fixing of Friday, November 22, 2019 as the Record Date for this purpose.

Intimation about Board Meeting scheduled to be held on Thursday, November 07, 2019 to inter alia, consider and approve the Unaudited financial results (both Stand-alone and Consolidated) for the quarter / half year ended September 30, 2019, and to consider payment of interim dividend, if any.

Intimation that  the representative(s) of Capital Investment Research Services Private Limited would be having a Con-call with us by 05.30 P.M. on Friday, October 04, 2019.

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from 1st October 2019 and will be reopened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the Quarter /Half-year ended September 30, 2019.

Intimation about the following forthcoming meeting / Con-call: (i) Con-call with the representative(s) of Sundaram Asset Management Company Limited, at 10.30 A.M. on Monday, September 30, 2019. (ii) Meeting with the representative(s) of Fundsmith LLP, at 2.30 P.M. on Tuesday, October 01, 2019.

At their meeting held today, the Audit Committee reviewed the valuation reports of Nueclear Healthcare Ltd., (NHL) received from Karvy Investor Services Ltd. and noted the long gestation period of this business in terms of returns. The Committee also felt that accepting the offer of Dr. A. Velumani, Chairman, MD & CEO, to acquire the entire shareholding in NHL may result in dilution of his focus and time, which is not in the interest of the Company. Hence, the Audit Committee recommended that it is not expedient to accept the offer of Dr. A. Velumani at this juncture. The Board, which met subsequently, accepted the above recommendation of the Audit Committee. None of the promoter-directors, were present during the discussions at the Audit Committee Meeting and at the meeting of the Board of Directors.

Intimation about Board Meeting scheduled to be held on Saturday, September 21, 2019 to consider the report of valuation of the wholly owned subsidiary company, Nueclear Healthcare Limited (NHL), obtained from a second valuer engaged for the purpose, in the context of deciding whether to retain the Company’s shareholding in NHL or dispose it of.

Intimation about the following forthcoming meetings: (i) Meeting with the representative(s) of Sunidhi Securities & Finance Limited, at 4.00 P.M. on Thursday, September 19, 2019. (ii) Meeting with the representative(s) of India Ratings & Research (Fitch Group), at 4.00 P.M. on Friday, September 20, 2019.

Intimation that  the representative(s) of Angle Broking Limited would be having a Con-call with us by 11.00 A.M. on Monday, September 16, 2019.

Intimation about meeting of representative(s) of SAIF Partners, with us at 10.30 A.M. on Tuesday, August 27, 2019 at the Corporate Office of the Company.

Intimation that Mr. Anand Velumani, Director, Nueclear Healthcare Limited, our wholly owned subsidiary, would be participating at the ‘15th Annual Global Investor Conference’ organized by M/s. Motilal Oswal Financial Services Limited, at Hotel Grand Hyatt, Mumbai on 20th August, 2019, where representatives of various fund houses would be meeting him.

Intimation about conference call for Indian and Overseas Investors to be held on 14-08-2019 to discuss about Unaudited financial results (Stand-alone and Consolidated) for the quarter ended 30-06-2019 Click here to see the invite

Intimation about the outcome of the Board Meeting held on 10-08-2019 (i) Approval of Unaudited financial results (Stand-alone and Consolidated) for the quarter ended 30-06-2019. (ii) Approval of issue and allotment of new equity shares not exceeding 37,859 shares to those employees who may be exercising the Stock Options granted to them in 2016 and vesting on them on 12th September 2019, subject to compliance with applicable regulations.

Intimation about Board Meeting scheduled to be held on Saturday, August 10, 2019 to inter alia, consider and approve the Unaudited financial results (both Stand-alone and Consolidated) for the quarter ended June 30, 2019.

Intimation about (i) 19th Annual General Meeting convened to be held on 24-08-2019 at 3.00 P.M. at Hotel Yogi Midtown, Turbhe , Navi Mumbai, (ii) Book-Closure from 18-08-2019 to 24-08-2019 (both days inclusive) for payment of final dividend of Rs.20/- (on approval by shareholders), & (iii) E-voting facility available to the Shareholders.

Intimation about meeting of representative(s) of Baring Private Equity Asia, with us at 3.30 P.M. on Friday, July 05, 2019, at the Corporate Office of the Company, followed by a visit to our Lab.

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with immediate effect and will be reopened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the Quarter ended June 30, 2019.

Intimation about the following forthcoming meetings: (i) Meeting with the representative(s) of PhillipCapital India Private Limited, at 3.30 P.M. on Wednesday, July 03, 2019. (ii) Meeting with the representative(s) of Centrum Capital Ltd., at 4.30 P.M. on Friday, July 05, 2019.

Post-script of the conference call of Indian and Overseas Investors held on 21-05-2019 to discuss about audited financial results (stand-alone & consolidated) for the year ended 31-03-2019. Click here

Intimation about the following forthcoming meetings: (i) Meeting with the representative(s) of Securities Investment Management Pvt. Ltd., at 3.30 P.M. on Wednesday, June 26, 2019. (ii) Meeting with the representative(s) of HDFC Securities Limited, at 4.30 P.M. on Wednesday, June 26, 2019.

Intimation that while considering the offer made by Dr. A. Velumani, Chairman, MD & CEO to acquire the Company’s shareholding in NHL, both the Audit Committee and the Board of Directors have unanimously decided that the Company has to determine whether it would be beneficial for the Company to hive off the subsidiary or retain it, and for this purpose, it would be advisable to obtain one more valuation report to ensure that the valuation of the subsidiary has been correctly ascertained. The Committee decided to appoint a SEBI approved merchant banker to submit a valuation report, within the shortest possible time, and then take a decision.  None of the Promoter-directors were present during the discussions.

Intimation about the following forthcoming meetings: (i) Meeting with the representative(s) of Sundaram Mutual Fund, at 10.30 A.M. on Saturday, June 15, 2019. (ii) Meeting with the representative(s) of Reliance Mutual Fund, at 12.00 Noon on Saturday, June 15, 2019. (iii) Meeting with the representative(s) of Banyan Capital Advisors LLP, at 10.00 A.M. on Wednesday, June 19, 2019. (iv) Meeting with the representative(s) of Grandeur Peak Global Advisors, at 02.00 P.M. on Thursday, June 27, 2019.

Intimation that a meeting of the Board of Directors will be held on Thursday, June 13, 2019, to discuss about the offer made by Dr. A. Velumani, Chairman, Managing Director & CEO to acquire the shareholding of the Company in Nueclear Healthcare Limited (NHL), the wholly owned subsidiary of the Company.

Intimation about the following forthcoming meetings: i) Meeting with the representative(s) of CWC Advisors, at 02.00 P.M. on Tuesday, May 28, 2019 at the Corporate Office of the Company. ii) Meeting with the representative(s) of Mirabilis Investment Trust, at 04.00 P.M. on Wednesday, May 29, 2019 at the Corporate Office of the Company. iii) Participation of our representative(s) at “Trinity India- 2019” Organized by Batlivala & Karani Securities India Pvt. Ltd. at Hotel Trident, BKC on Friday, May 31, 2019 from 10.00 A.M., where representatives of various fund houses would be met.  

Intimation that  the representative(s) of SAIF Partners would be having a Con-call with us by 3.00 P.M. on Thursday, May 23, 2019.  

Intimation about meeting of representative(s) of Anived Portfolio Managers Private Limited, with us at 02.00 P.M. on Wednesday, May 22, 2019 at the Corporate Office of the Company.

Intimation that we had participated in the tender floated by Municipal Corporation of Greater Mumbai (the “MCGM”) for outsourcing of laboratory investigative services “Aapli Chikitsa”, and we have  now received a  letter from MCGM informing us that our tender has been accepted by them; we have been  authorized to provide laboratory investigative services “Aapli Chikitsa” over  a period of 4 years from the commencement of operations, to the MCGM affiliated hospitals and clinics in Western Suburban Zone and City Zone  of Mumbai. The total contract cost of the tender to be executed over the period of 4 years is Rs. 532.27 million, with an assurance of about 60% of total samples test per year; we have since complied with the terms and conditions and are poised to commence the operation on tender awarded by Municipal Corporation of Greater Mumbai for availing laboratory investigative services “Aapli Chikitsa” within next 30 days.

Intimation that at the Board Meeting held on 18-05-2019, when the Auditors pointed out the impairment of investment in Nueclear Healthcare Limited (NHL), the wholly owned subsidiary, Dr. A. Velumani, Chairman, Managing Director & CEO has offered to buy the entire shareholding of the Company in NHL at the current investment value of Rs. 194.67 crores to ensure that there is no loss to the public shareholders; however, all required formalities will be complied with by the Company for such a transaction; we were waiting for the concurrence from the Auditors to intimate this and hence the delay.  

Intimation about conference call for Indian and Overseas Investors to be held on 21-05-2019 to discuss about Audited financial results (Stand-alone and Consolidated) for the quarter / full year ended 31-03-2019 Click here to see the invite

Intimation of decisions taken at the Board Meeting held on May 18, 2019, about approval of the Audited Financial Statements (both Stand-alone and Consolidated) for the quarter and the whole year ended 31-03-2019, Recommendation of a Dividend of Rs.20/- per share for 2018-19 and granting of Stock Options for employees for 2018-19.

Intimation about Board Meeting scheduled to be held on Saturday, May 18, 2019 to inter alia, consider and approve the audited financial results (both Stand-alone and Consolidated) for the year ended  31st March 2019, to consider declaration of dividend, if any, and to consider issue of stock options to employees for 2018-19. Intimation about closure of Trading Window for Directors, Employees and Connected Persons from April 26, 2019 (as already announced) up to end of the day on May 21, 2019.

Intimation about meeting of representative(s) of SAIF Partners, with us at 10.00 A.M. on Thursday, May 02, 2019 at the Corporate Office of the Company, followed by a visit to our Lab.

Intimation that Trading Window shall remain closed for Directors, Employees and Connected Persons from April 26, 2019 until 48 hours after announcement of the financial results for FY 2018-19. The actual date of re-opening of trading window will be notified in due course.

Confirmation of compliance of provisions of Reg. 74(5) of SEBI (Depositories & Participants) Regulations 2018, as certified by the Company’s RTA

Intimation about non-applicability of framework for Fund Raising by issue of Debt Securities by Large Entities notified by SEBI

Intimation that representative(s) of TA Associates, would be having a meeting with us at 2.30 P.M. on Thursday, April 11, 2019 at the Corporate Office of the Company, followed by a visit to our Lab.  

Intimation about the following analyst meetings to be held at our corporate office: i) Meeting with the representative(s) of Arisaig Partners, at 03.00 P.M. on Friday, April 05, 2019, to be followed by a visit by them to our Lab. ii) Meeting with the representative(s) of Edelweiss Securities Limited, at 3.30 P.M. on Friday, April 05, 2019, to be preceded by a visit by them to our Lab.

Intimation about the following Analyst Meetings: i) Meeting with the representative(s) of Sands Capital Management, at 12.30 P.M. on Monday, March 25, 2019 at the Corporate Office of the Company, followed by Lab Visit. ii) Participation of our representative at 1st Annual Edition of “INDIA IDEATION CONFERENCE” Organized by Motilal Oswal at Hotel Grand Hyatt, Mumbai on Wednesday, March 27, 2019 from 9.00 A.M. to 6.00 P.M, where he will meet representatives of various fund houses. iii) Meeting with the representative(s) of Goldman Sachs India Securities Ltd., at 3.30 P.M. on Friday, March 29, 2019 at the Corporate Office of the Company.

Intimation about the following Analyst Meetings : i) Meeting of the representative(s) of Way2Wealth, a Coffee Day Company, at 11.30 A.M. on Wednesday, March 20, 2019 at the Corporate Office of the Company. ii) Meeting of the representative(s) of SAIF Partners, at 06.00 P.M. on Monday, March 25, 2019 at Hotel Grand  Hyatt, Mumbai.

Intimation about the following Analyst Meetings / Con-call, to be held at our corporate office: i) Con-call between us and the representatives of Motilal Oswal Mutual Fund, at 3.00 P.M. on Monday, March 11, 2019. ii) Meeting of the representative(s) of Capital International, at 09.30 A.M. on Tuesday, March 12, 2019. iii) Meeting of the representative(s) of Seven Canyons Advisors, at 10.00 A.M. on Wednesday, March 13, 2019.

Intimation about the outcome of the Board Meeting held on 09-03-2019 – Appointment of Dr. Indumati Gopinathan as an Independent Director for a period of five years with immediate effect.

Intimation about the following analyst meetings to be held at our corporate office:  i) Meeting of the representative(s) of TA Associates, at 10.00 A.M. on Tuesday, February 26, 2019. ii) Meeting of the representative(s) of Haitong Securities India Private Limited, at 3.30 P.M. on Wednesday, February 27, 2019.

Intimation about the following analyst meetings to be held at our corporate office:  i) Meeting of the representative(s) of Lohia Securities Limited, at 11.00 A.M. on Monday, February 25, 2019. ii) Meeting of the representative(s) of TR Capital, at 11.00 A.M. on Tuesday, February 26, 2019.

Post-script of the conference call of Indian and Overseas Investors held on 12-02-2019 to discuss about unaudited financial results (stand-alone & consolidated) for the quarter /nine months ended 31-12-2018 Click here

Intimation about the following analyst meetings to be held at our corporate office:  i) Meeting of the representative(s) of Consortium Securities Private Limited, at 3.30 P.M. on Friday, February 22, 2019. ii) Meeting of the representative(s) of Pragya Equities Private Limited, at 5.00 P.M. on Wednesday, February 27, 2019.

Intimation that Ms. Alka Katiyar, Research Associate- Pharma Institutional Equities of IndiaNivesh Securities Limited would be having a meeting with Mr. Sachin Salvi, General Manager-Finance, at our office by 11.00 A.M. on Tuesday, December 11, 2018.

Intimation that Mr. Robert Harvey and Mr. Taizo Ishida, Portfolio Managers of Matthews Asia would be having a meeting with  Mr. Anand Velumani, Director of our wholly owned subsidiary, Nueclear Healthcare Limited, and Mr. Aditya Shinde,Deputy  General Manager- Finance at Hotel Trident, BKC by 09.00 A.M. on Wednesday, December 05, 2018.

Intimation that Mr. Shrikant Akolkar, Senior Analyst- Pharma of IIFL Securities Limited would be having a meeting with Mr. Sachin Salvi,  General Manager-Finance, at our office by 11.00 A.M. on Tuesday, December 04, 2018.

Intimation that Ms. Charvi Pandey, Analyst of Fidelity International would be having a meeting with Mr. Sachin Salvi, General Manager-Finance, at our office by 10.00 A.M. on Tuesday, December 11, 2018 and she will also visit our CPL after meeting.

Intimation that Mr. Kalpesh Parekh, Vice President- Institutional Sales and Mr. Surajit Pal, Analyst of Prabhudas Lilladher Pvt. Ltd. would be having a meeting with Dr. Caesar Sengupta, Vice-President- Operations and Mr. Sachin Salvi, General Manager-Finance, at our office by 03.30 P.M. on Wednesday, December 05, 2018.

Intimation that Mr. Anand Velumani, Director of our wholly owned subsidiary, Nueclear Healthcare Limited, and Mr. Aditya Shinde, Deputy General Manager- Finance would be participating at B & K’s Investor Conference- Emergent India- 2018 organized by M/s. Batlivala & Karani Securities India Pvt. Ltd., at Hotel Trident BKC, Mumbai, on Wednesday, 5th December 2018, where the representatives of various Funds would be meeting, from 10.00 A.M to 6.00 P.M.

Intimation that Mr. Navin Ramachandran, Fund Manager and Mr. V. Srinath, Senior Analyst of Bellwether Capital would be having a meeting with Mr. Sachin Salvi, General Manager-Finance, at our office by 02.30 P.M. on Wednesday, November 28, 2018.

Intimation that Mr. Anand Velumani, Director of our wholly owned subsidiary, Nueclear Healthcare Limited, and Mr. Aditya Shinde, Deputy General Manager- Finance would be participating at Annual C.H.A.M.P.S. Conference organized by M/s. Spark Capital Advisors (India) Private Limited, at Hotel Trident BKC, Mumbai, on Friday, 16th November 2018, where they would be meeting representatives of various Funds, between 10.00 A.M. and 2.00

Post-script of the conference call of Indian and Overseas Investors held on 12-11-2018 to discuss about unaudited financial results (stand-alone & consolidated) for the quarter /half year ended 30-09-2018.View Here

Intimation that Mr. Sachin Salvi, General Manager-Finance, would be participating at IDFC Securities Annual Investor Conference ‘The Stock called India’ organized by M/s. IDFC Securities Limited, at Hotel Grand Hyatt, Mumbai, on Wednesday, 21st November 2018, where he would be meeting various investors between 2.00 P.M and 6.00 P.M.

Intimation about conference call for Indian and Overseas Investors to be held on 12-11-2018 to discuss about Unaudited financial results (Stand-alone and Consolidated) for the quarter / half year ended 30-09-2018.Click to see invite Here

Intimation about the outcome of the Board Meeting held on 03-11-2018 – Approval of unaudited financial results for the quarter/half year ended 30-09-2018 and approval of issue & allotment of 33,973 equity shares to eligible employees who have exercised the Options granted to them in 2015.

Intimation that Mr. Suney Hindocha and Mr. Edward Lam, Fund Managers of Somerset Capital Management, UK, would be having a meeting with Dr. Caesar Sengupta, Vice-President-Operations, Mr. Sachin Salvi, General Manager-Finance and Mr. Anand Velumani, Director of our subsidiary company, Nueclear Healthcare Ltd., at our office by 9.30 A.M. on Thursday, November 22, 2018.

Intimation that Mr. Stephen Farley, Managing Partner and Mr. Andrei Stetsenko, Partner of Farley Capital, New York would be having a meeting with Dr. Caesar Sengupta, Vice-President-Operations, Mr. Sachin Salvi, General Manager-Finance and Mr. Anand Velumani, Director of our subsidiary company, Nueclear Healthcare Ltd., at our office by 9.30 A.M. on Thursday, November 15, 2018.

Intimation about Board Meeting scheduled to be held on November 03, 2018, to inter alia, consider and approve the unaudited financial results (both Stand-alone and Consolidated) for the quarter / half year ended 30th September 2018. Intimation about closure of Trading Window for Directors, Employees and Connected Persons from October 25, 2018 to November 06, 2018 (both days inclusive).

Intimation that Mr. Krishnakumar, CIO of Sundaram Mutual Fund would be having a con-call with our Chairman & Managing Director, Dr. A. Velumani on Friday, October 05, 2018, by 10.00 A.M.

Intimation about meeting of Mr. Sunil Asnani, Portfolio Manager, of Matthews International Capital Management, with one or more of the following, viz. Mr. Anand Velumani, Dr. Caesar Sengupta, Vice President-Operations, Mr. Sachin Salvi, General Manager-Finance, and Mr. Vatsal Goyal, Head-Strategy & Corporate Development, at our office by 04.00 P.M. on Monday, September 10, 2018.

Intimation about participation of Mr.Anand Velumani, and Mr. Aditya Shinde, Deputy General Manager-Finance in the Investor Conference organised by Motilal Oswal Securities Limited, at Hotel Grand Hyatt on Tuesday and Wednesday, August 28 and 29, 2018. View here

Intimation about meeting of Mr. Kalpraj Dharamshi, Promoter of Dharamshi Securities Private Limited & Valuequest Investment Advisors P.Ltd., with our Chairman, Managing Director and CEO, Dr. A. Velumani, at our office by 11.30 A.M. on Friday, September 07, 2018.

Intimation that Mr. Masahiro Kanezaki , Portfolio Manager of Portfolia Japan, who would meet our Chairman, Managing Director & CEO, Dr.A. Velumani on 06-09-2018, is a client of Kim Eng Securities India P. Ltd., and not part of Maybank, as earlier reported by us.

Intimation about meeting of Mr. Apurv Kulkarni, Senior Analyst of Nine Rivers Capital Holdings Pvt. Ltd., with Dr. Caesar Sengupta, Vice-President-Operations, Mr. Sachin Salvi, General Manager-Finance and Mr. Vatsal Goyal, Head- Strategy and Corporate Development, at our office by 2.00 P.M. on Tuesday, August 28, 2018.

Post-script of the conference call of Indian and Overseas Investors held on 14-08-2018 to discuss about unaudited financial results (stand-alone & consolidated) for the quarter ended 30-06-2018. View Here

Intimation about meeting of Mr. A. N. Seshadri, Principal and Mr. Gaurav Kothari, Fund Manager of Nalanda Capital, with our Chairman, Managing Director & CEO, Dr. A. Velumani and other key managerial personnel, at our office from 2.30 P.M. on Tuesday, August 21, 2018.

Intimation about meeting of Mr. Masahiro Kanezaki, Portfolio Manager of Portfolia Japan, a part of Maybank, Malaysia, with our Chairman, Managing Director & CEO, Dr. A. Velumani, at our office by 9.30 A.M. on Thursday, September 06, 2018.

Intimation about conference call of Indian and Overseas Investors to be held on 14-08-2018 to discuss about Unaudited financial results (Stand-alone and Consolidated) for the quarter ended 30-06-2018.

Intimation about meetings of the following with our Chairman & Managing Director, Dr. A. Velumani, at our office tomorrow, 14th August 2018. 1. Mr. Dilip Bhat, Managing Director and Mr. Vishal Purohit, Head Equities of Prabhudas Lilladher by 2.00 P.M 2. Mr. Kahlil Randeria of New Horizon, by 4.00 P.M.

Intimation about approval of the Unaudited Financial Statements (both Stand-alone and Consolidated) for the quarter ended 30-06-2018 at the Board Meeting held on 11-08-2018.

Intimation that the 18th Annual General Meeting (originally scheduled to be held on 11-08-2018) has been postponed to 01-09-2018 due to unavoidable circumstances and administrative reasons, that formal notice will be sent to the shareholders separately, and that there is no change in book closure dates.

Intimation of Outcome of the Board Meeting held on August 04, 2018, (i. ) to approve a proposal of buy back of equity shares for a total amount of Rs. 63,00,00,000/- (Rupees sixty three crores) from existing shareholders (other than Promoters & Promoter group) at a maximum price of Rs. 730/- per share through Open Market route through stock exchanges and (ii) to postpone the 18th AGM convened for 11-08-2018 to be held on 01-09-2018.

Intimation about Board Meeting scheduled to be held on August 11, 2018, to inter alia, consider and approve the unaudited financial results (both Stand-alone and Consolidated) for the quarter ended 30th June 2018.

Intimation about Board Meeting scheduled to be held on August 04, 2018, to consider the proposal of buy back of equity shares and postponement of AGM convened to be held on 11-08-2018 to a later date. Intimation about closure of Trading Window for employees, directors & connected persons, from July 30, 2018 to August 14, 2018 (both days inclusive).

Intimation about the meeting of Mr. Sudarshan Padmanabhan, Research Analyst-Investment, of Sundaram Asset Management Company Limited, with our Chairman & Managing Director, Dr. A. Velumani, at our office by 12.00 Noon on Wednesday, July 18, 2018.

Intimation about the meeting of Ms. Charulata Gaidhani and Mr. Milind Karmarkar, Research Analysts of Dalal & Broacha Stock Broking Pvt. Ltd., with our General Manger-Finance, Mr. Sachin Salvi and Head-Strategy and Corporate Development, Mr. Vatsal Goyal, at our office by 3.30 P.M. on Tuesday, 26th June 2018.

Intimation about the meeting of Mr. Ashwin Reddy of Samatva Investments, with our General Manager-Finance, Mr. Sachin Salvi at our office by 11.00 A.M. on Friday, 08th June 2018.

Intimation about the meeting of Ms.Roopa Raman of International Finance Corporation (IFC), with our General Manger-Finance, Mr. Sachin Salvi and Head-Strategy and Corporate Development, Mr. Vatsal Goyal, at our office by 11.00 A.M. today (Wednesday, 23rd May 2018).

Post-script of the conference call of Indian and Overseas Investors held on 03-05-2018 to discuss about audited financial results (stand-alone & consolidated) for the quarter/whole year ended 31-03-2018.View Here

Intimation about the meeting of Mr. Sandip Patodia, Equity Analyst of Fundsmith LLP, with our Chairman & Managing Director, Dr. A. Velumani, General Manager- Finance, Mr. Sachin Salvi and Head- Strategy and Development, Mr. Vatsal Goyal, at our office by 10.30 A.M. on Wednesday, 06th June 2018, and his visit to our Lab in the morning before the meeting.

Intimation about meeting of Mr. Vinod Jayaram, Senior Investment Analyst, of Elara Capital, with our General Manager- Finance, Mr. Sachin Salvi and Head- Strategy and Development, Mr. Vatsal Goyal, at our office by 11.00 A.M. on Thursday, 10th May 2018.

Intimation about conference call of Indian and Overseas Investors to be held on 03-05-2018 to discuss about Audited financial results (Stand-alone and Consolidated) for the quarter/whole year ended 31-03-2018.

Intimation of decisions taken at the Board Meeting held on April 28, 2018, about approval of the Audited Financial Statements (both Stand-alone and Consolidated) for the quarter and the whole year ended 31-03-2018, Recommendation of Final Dividend of Rs.5/- per share and granting of Stock Options for employees for 2017-18, and other decisions taken at the Meeting.

Intimation about Board Meeting scheduled to be held on April 28, 2018, to approve Audited financial results (Stand-alone and Consolidated) for the quarter/year ended 31-03-2018, to consider recommending final dividend, if any,for 2017-18 and to consider granting stock options to employees for 2017-18. Intimation about Closure of Trading Window for employees, directors & connected persons, from April 11, 2018 to May 02, 2018.

Intimation about meeting of Mr. Bharat Shah of ASK Wealth Management, with our Chairman & Managing Director, Dr. A. Velumani, at our office by 11.00 A.M. on Tuesday, 03rd April 2018.

Intimation about meeting of our Chairman & Managing Director, Dr. A. Velumani, with Mr. Nitin Bajaj of FIL India Business and Research Services Private Limited, at their office by 5.30 P.M. on Monday, 19 March 2018.

Intimation about meeting of Mr. Kantor of Allard Partners, Hong Kong with Mr. Sachin Salvi, General Manager-Finance, by 9.00 A.M. on Wednesday, March 14, 2018, at our office, and his visit to our Central Processing Laboratory prior to the meeting.

Post-script of the conference call of Indian and Overseas Investors held on 09-02-2018 to discuss about unaudited financial results (stand-alone & consolidated) for the quarter/nine months ended 31-12-2017. View Here

Intimation about conference call of Indian and Overseas Investors to be held on 09-02-2018 to discuss about unaudited financial results (stand-alone and consolidated) for the quarter/nine months ended 31-12-2017.

Intimation of decisions taken at the Board Meeting held on February 03, 2018, about approval of the Unaudited Financial Statements (both Stand-alone and Consolidated) for the quarter and nine months ended 31-12-2017, as per IND-AS Standards and other decisions taken at the Meeting. Intimation of declaration of interim dividend of Rs.5/- per share for FY 2017-18, and fixing of Friday, February 16, 2018 as the Record Date for this purpose.